Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
about
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Trelagliptin: First Global Approval.Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 studyEffect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.Investigational insulin secretagogues for type 2 diabetes.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.Effects of glucose-lowering agents on ischemic stroke.Patient Perspectives on Combination Therapy of a Once-weekly Oral Medication Plus Daily Medication for Lifestyle-related Chronic Diseases.Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.A fluorescent switchable AIE probe for selective imaging of dipeptidyl peptidase-4 in vitro and in vivo and its application in screening DPP-4 inhibitors.Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin.Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.
P2860
Q30249371-4D1EF62A-A4CF-4F78-9759-70F330E913A5Q30846870-B6FDFA9E-BBD2-4BB9-83E0-013F874923BEQ34482528-2AE6A0E2-676C-4100-947D-80F32B8649E7Q36058025-07EE0D18-66FA-4744-B93D-51003CE33D6CQ37227394-87292F0B-1ED2-4289-A7EF-C91164EBA125Q38372172-12BD5732-04D0-4DDC-A99E-827755EB290FQ38614486-57775542-8D80-433B-8927-5D78A95E17EEQ38622203-5E5FE568-785F-4170-98B5-ABBCD47DDB52Q38644587-0A345108-E424-400C-A211-511A786B6C1BQ38716033-B2949C14-2B84-464C-89F7-CB4AE73E7C19Q38735419-F006DE87-38A4-4D95-B99A-146B00C714DFQ38866310-5969673D-C1AA-4931-AB31-7F8FAECD16D9Q39266678-5F7E0FF0-0200-4F89-8F99-2BDC4FB939DCQ39427199-D4F157D4-BD16-46A6-8B0D-A7ED41F33C54Q41864289-1898B247-15A7-44D9-92CB-57502D8EC2C5Q42620088-709519FE-1700-4795-BBB7-5B621097E2F6Q42815001-DC368027-FB59-4BB7-95B0-1D09F651EEA1Q47133131-B5D284D6-9AE7-4129-A540-54EEC34A97FDQ48183459-4F950398-8891-43A5-BEAF-934C915A75E0Q52590826-92090558-5C10-4067-A353-001F4248A008Q55426168-CE05086B-D26C-4C1D-9AAA-6BD3D4F901C0
P2860
Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@ast
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@en
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@nl
type
label
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@ast
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@en
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@nl
prefLabel
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@ast
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@en
Once-weekly trelagliptin versu ...... hase 3, non-inferiority study.
@nl
P2093
P1476
Once-weekly trelagliptin versu ...... phase 3, non-inferiority study
@en
P2093
Hideaki Maezawa
Hitoshi Onouchi
Kohei Kaku
Shingo Kuroda
P304
P356
10.1016/S2213-8587(14)70251-7
P577
2015-01-19T00:00:00Z